Skip to main content

Table 3 Outcomes of the included systematic reviews

From: An evidence mapping of systematic reviews and meta-analysis on traditional Chinese medicine for ulcerative colitis

No. Study ID (first author, year) Outcomes (+: for positive, −: for negative)
1 Gong Y2014 Total effectiveness (+) RR 1.22 [1.15, 1.30], Adverse reaction rate (+)
2 Li WH2013 Total effectiveness (+) OR 5.50 [3.74, 8.08], Cure rate (+) OR 3.26 [2.44, 4.35], Adverse reaction rate (+)
3 Zuo HB2013 Total effectiveness (+) RR 1.75 [1.24, 2.48], Adverse reaction rate (+), Clinical symptoms (+), Electron enteroscopy results (+)
4 Pei QW2012 Total effectiveness (+) OR 3.87 [2.47, 6.05], Adverse reaction rate (+)
5 Wen Y2017 Clinical effectiveness (+) RR 1.55 [1.39, 1.72], Adverse reaction rate (+), DAI (+), TNF-a (+), IL-17 (+), CRP (+)
6 Chen K2016 Total effectiveness (+) OR 3.30 [2.25, 4.82], significant effectiveness (+) OR 2.02 [1.54, 2.65], inefficiency rate (+) OR 0.30 [0.21, 0.44]
7 Lu2017 Inefficiency rate (+) OR 0.26 [0.20, 0.35], recurrence rate (+), DAI (+), TNF-a (+), IL-17 (+), IL-23 (+), CRP (+)
8 Wang XY2017 Total effectiveness (+) OR 4.44 [2.65, 7.44], Cure rate (+) OR 1.72 [1.08, 2.75], Adverse reaction rate (+), Recurrence rate (+)
9 Wei Y2018 Clinical effectiveness (+) OR 6.03 [1.95, 16.46]
10 Zhang LH2018 Total effectiveness (+) OR 4.32 [2.55, 7.31], Adverse reaction rate (+), Recurrence rate (+)
11 Li HB2017 Total effectiveness (+) OR 4.69 [3.00, 7.34], Adverse reaction rate (−)
12 Li HB2018 Total effectiveness (+) OR 2.16 [1.28, 3.63], Adverse reaction rate (−), TCM syndrome (−), mucosal lesion (+)
13 Huang FMZ2014 Total effectiveness (+) RR 1.20 [1.15, 1.26], Recurrence rate (+), DAI (+), TCM syndrome (+), IgA* (+), IgM* (+), IgG* (+), Symptom relief time (+), stool occult blood (+), performance of colonoscopy (+)
14 Li HB-a2018 Total effectiveness (+) OR 3.12 [2.11, 4.60], Adverse reaction rate (+), abdominal pain (+), diarrhea (−), pus and blood stool (−)
15 Liu G2011 Total effectiveness (+) OR 0.18 [0.11, 0.32]
16 Gu SZ2018 Total effectiveness (+) RR 1.17 [1.12, 1.21], Adverse reaction rate (−), TCM syndrome (+), DAI (+)
17 Xiong AQ2011 Clinical effectiveness (+) OR 3.71 [2.26, 6.10]
18 Lv C2014 Total effectiveness (+) RR 1.20 [1.13, 1.28], Adverse reaction rate (+), Recurrence rate (−), IL-13 (+), IL-8 (−), ESR (−), CRP (−), TCM syndrome (+), IgG (+), abdominal pain (+), diarrhea (+), pus and blood stool (+), Geboes (+), Mucosal biopsy score (−), performance of colonoscopy (+), Time of bellyache disappearance (+), Time of diarrhea disappearance (−)
19 Wang DY2011 Clinical effectiveness (+) RR 1.26 [1.11, 1.43], Adverse reaction rate (+), Recurrence rate (+), pus and blood stool (−), performance of colonoscopy (+)
20 Liu TW2016 Total effectiveness (+) RR 1.20 [1.14, 1.27], Adverse reaction rate (−)
21 Yang L2017 Clinical effectiveness (+) RR 1.31 [1.19, 1.44], IL-6 (+), IL-8 (+), performance of colonoscopy (+), TCM syndrome (+),
22 Zhang WN2017 Total effectiveness (+) RR 1.23 [1.15, 1.32]
23 Chen F2012 Clinical effectiveness (+) RR 1.27 [1.21, 1.34], Recurrence rate (+), performance of colonoscopy (+)
24 Yan SG2013 Total effectiveness (+) OR 4.18 [2.95, 5.91], cure rate (+) OR 2.86 [2.17, 3.76], Recurrence rate (+)
25 Xiong J2008 Clinical effectiveness (+) OR 4.19 [2.89, 6.07], cure rate (+) OR 3.12 [2.34, 4.15], Recurrence rate (+)
26 Chen MY2018 Total effectiveness (−) RR 0.99 [0.91, 1.08], Adverse reaction rate (+), DAI (−), performance of colonoscopy (+)
27 Chen MY2018-a Total effectiveness (+) RR 1.20 [1.13, 1.26], Adverse reaction rate (−), Recurrence rate (+), performance of colonoscopy (+), Time of bellyache disappearance (+), Time of diarrhea disappearance (−), Time of hematochezia disappearance (+)
28 Cui DJ2012 Clinical effectiveness (−) RR 0.97 [0.70, 1.35], Adverse reaction rate (−),
29 Ma XM2012 Total effectiveness (+) OR 5.29 [3.67, 7.63], cure rate (+) OR 3.65 [2.61, 5.12], Adverse reaction rate (+), DAI (+), performance of colonoscopy (+), abdominal pain (+), diarrhea (+), pus and blood stool (+)
30 Lai YL2013 Total effectiveness (+) RR 1.14 [1.06, 1.23], cure rate (+) RR 1.54 [1.18, 2.00], Adverse reaction rate (+)
31 Zhu JB2016 Total effectiveness (+) OR 5.20 [2.63, 10.29]
32 Huang ZB2014 Total effectiveness (+) OR 4.05 [2.98, 5.50], cure rate (+) OR 3.24 [2.57, 4.09], Adverse reaction rate (+)
33 Qi J2016 Total effectiveness (+) OR 4.97 [1.73, 14.33], cure rate (+) OR 3.51 [1.92, 6.42]
34 luo Y2012 Total effectiveness (+)
35 Xu P2015 Total effectiveness (+) OR 4.28 [3.16, 5.79], Adverse reaction rate (+), DAI (+), IL-6 (−), performance of colonoscopy (+), Time of bellyache disappearance (+), Time of diarrhea disappearance (+), Time of hematochezia disappearance (+), Time of fever disappearance (+)
36 Gong YD2012 Clinical effectiveness (+) OR 4.54 [3.29, 6.18], DAI (+), ESR (+), performance of colonoscopy (+), IgA (−), IgM (+), IgG (−), Whole blood viscosity score (−), plasma viscosity (+), abdominal pain (+), diarrhea (+), pus and blood stool (+), tenesmus (+)
37 Ma DZ2015 Clinical effectiveness (+) OR 4.2 [2.72, 6.49]
38 Huang SG2010 Clinical effectiveness (+) OR 6.67 [4.22, 10.53]
39 Ni XX2019 Total effectiveness (+) RR 1.20 [1.15, 1.25], Adverse reaction rate (+), Recurrence rate (+), performance of colonoscopy (+), TCM syndrome (+)
40 Jiang T2006 Clinical effectiveness (+), Total effectiveness (+) OR 0.24 [0.14, 0.39], Adverse reaction rate (+)
41 Zhu XG2012 Total effectiveness (+) OR 6.10 [4.33, 8.60]
42 You WF2017 Clinical effectiveness (+) OR 6.34 [3.97, 10.14]
43 Cui DJ-a2012 Total effectiveness (+) RR 1.16 [1.07, 1.25], Adverse reaction rate (+), Recurrence rate (+)
44 Wu Zl2017 Total effectiveness (+) RR 1.25 [1.19, 1.31], Adverse reaction rate (+), Recurrence rate (+), ESR (+)
45 Huang HJ2012 Total effectiveness (+) OR 13.36 [4.90, 36.46], Cure rate (+) OR 4.55 [2.90, 7.14]
46 Zha AS2015 Total effectiveness (+) RR 1.248 [1.187, 1.313], Adverse reaction rate (+)
47 Hou LW2017 Clinical effectiveness (+), Total effectiveness (+) RR 1.24 [1.18, 1.30], Adverse reaction rate (+), Recurrence rate (+), performance of colonoscopy (+)
48 Hou LW2015 Clinical effectiveness (+), Total effectiveness (+) RR 1.32 [1.23, 1.41], Cure rate (+) RR 1.91 [1.35, 2.70], Adverse reaction rate (+), Recurrence rate (+), performance of colonoscopy (+), TCM syndrome (+)
49 Gan YK2015 Clinical effectiveness (+) OR 3.36 [1.96, 5.76]
50 Zhu JM2011 Clinical effectiveness (+) RR 1.13 [1.04, 1.23], performance of colonoscopy (−), TCM syndrome (+)
51 Wang DY2013 Clinical effectiveness (+) OR 5.16 [3.35, 7.95], Cure rate (+) OR 2.9 [2.10, 3.98], Adverse reaction rate (+), Recurrence rate (+)
52 Wang Y2018 Bifidobacterium level (+), Lactobacillus level (+), Enterococcus level (+), E. coli level (+)
53 He M2007 Clinical effectiveness (+), Total effectiveness (+) OR 0.26 [0.16, 0.42]
54 Pei QW2013 Total effectiveness (+) OR 5.06 [3.41, 7.52], Adverse reaction rate (+), performance of colonoscopy (+), TCM syndrome (+)
55 Yang AX2006 Clinical effectiveness (+), Total effectiveness (+) OR 6.60 [4.60, 9.47]
56 Zhu L2012 Clinical effectiveness (+) RR 1.17 [1.10, 1.25]
57 Jia JW2019 Total effectiveness (+) OR 4.99 [3.48, 7.14], IL-6 (+), IL-10 (+), CRP (+), Mucosal biopsy score (+)
58 Li L2019 Adverse reaction rate (+), Clinical efficacy (+) RR 4.93 [3.35, 7.26]
59 Chen MJ2019 Total effectiveness (+) OR 0.13 [0.08, 0.18], Adverse reaction rate (+)
60 Wu N2019 Total effectiveness (+) RR 1.23 [1.14, 1.31],Adverse reaction rate (+), IL-6 (+), TNF-α (+), IgA (+), IgG (+)
61 Peng JF2019 Total effectiveness (+) RR 1.17 [1.13, 1.21], Recurrence rate (+), Adverse reaction rate (+)
62 Fan 2019 Total effectiveness (+) RR 1.21 [1.12, 1.31], Recurrence rate (+), Adverse reaction rate (+),performance of colonoscopy (+)
63 Chi RT2019 Total effectiveness (+) OR 3.35 [2.45, 4.60], DAI (+),Adverse reaction rate (−), TCM syndrome (+), TNF-α (+),IL-17 (+), IL-23 (+), ESR (+), CRP (+)
64 Tang XJ2020 Total effectiveness (+) RR 1.18 [1.14, 1.23]
65 Liao ZW2020 Total effectiveness (+) RR 1.23 [1.16, 1.29], Recurrence rate (+), Adverse reaction rate (−), TNF-α (+), IL-6 (+), IL-8 (+), MPV (+), PLT (+), FIB(+)
66 Long TJ2020 Total effectiveness (+) OR 3.84 [2.07, 7.13], TCM syndrome (+), Mucosal biopsy score (+)
67 Long CW2021 Total effectiveness (+) RR 1.19 [1.07, 1.31], Cure rate (+) RR 1.72 [1.44, 2.06], Adverse reaction rate (+), ESR (−), CRP (+)
68 Bo HJ2020 Total effectiveness (+) RR 1.24 [1.18, 1.30],Recurrence rate (+), Adverse reaction rate (+), Efficacy of mucosal lesions (+)
69 Li PF2020 Total effectiveness (+) RR 1.31 [1.25, 1.37], Recurrence rate (+), Mayo score (+), Adverse reaction rate (+), TCM syndrome (+), Mucosal biopsy score (+)
70 Tan GZ2020 Total effectiveness (+) OR 4.90 [3.75, 6.41], Adverse reaction rate (+), Efficacy of mucosal lesions (+)
71 Hu QH2021 Clinical effectiveness (+) RR 1.20 [1.12, 1.29], TCM syndrome (+)
72 Yan ZX 2021 Clinical effectiveness (+) OR 3.87 [2.71, 5.51], Recurrence rate (+), Efficacy of mucosal lesions (+)
73 Yuan H2020 Clinical effectiveness (+) OR 0.22 [0.13, 0.39], Adverse reaction rate (+)
  1. 1.DAI DNA-dependent activator of IFN-regulatory factors 2. IL innammatory factors levels of interlekin 3. ESR erythrocyte sedimentation rate
  2. 4.CRP C-reaction protein 5. IgA immunoglobulin A 6. IgM immunoglobulin M 7. IgG immunoglobulin G 7.MPV meanplateletvolume 8.PLT platelet 9.FIB fibrinogen